肺高血压和肺移植等候名单对过敏性肺炎的结果
Michael J Nicholson1, Zehra Dhanani1, Shameek Gayen2
1Thoracic Medicine and Surgery, Temple University Hospital, Philadelphia, Pennsylvania.
JHLT open
|March 27, 2025
概括
过敏性肺炎患者肺高血压的新标准无法预测移植等候名单的存活率. 然而,高肺血管阻力 (PVR) ≥3Wu表明结果更差,有助于预后.
科学领域:
- 肺部病理学 肺部病理学
- 心脏病学 心脏病学
- 移植医学 移植医学
背景情况:
- 过敏性肺炎 (HP) 是一种间歇性肺部疾病,与增加的死亡率有关,通常是由于肺高血压 (PH).
- 最近欧洲心脏病学会的指导方针更新了毛囊前PH的诊断标准,将肺动脉平均压力 (mPAP) 从≥25mmHg降至≥20mmHg,肺血管阻力 (PVR) 从≥3Wu降至≥2Wu.
- 这些修订后的标准对等待肺移植的HP患者的预后的影响尚不清楚.
研究的目的:
- 评估新的毛囊前肺高血压诊断标准在预测过敏性肺炎患者等待名单存活时间方面的有用性.
- 在这个患者队列中,评估单个毛囊前肺高血压组件 (mPAP和PVR) 的预后价值.
主要方法:
- 使用移植接受者的科学注册表进行了一项回顾性队列研究.
- 列为肺移植的1175名HP患者根据旧和新标准对前毛细血管PH进行了分类,并根据mPAP (≤20mmHg,>20至<25mmHg,≥25mmHg) 和PVR (≤2Wu,>2至<3Wu,≥3Wu) 水平进行了分层.
- 卡普兰-梅尔分析和多变量考克斯回归被用来分析等候名单生存率.
主要成果:
- 卡普兰-梅尔分析显示了mPAP和PVR组的生存差异,主要由最严重的类别驱动.
- 多变量考克斯回归表明,根据更新的标准定义的不同毛囊前PH组之间的等候名单存活率没有显著差异.
- ≥3Wu的PVR与等候名单死亡率的增加显著相关.
结论:
- 欧洲心脏病学会对前毛囊性肺高血压的最新标准似乎不能独立预测过敏性肺炎患者等待列表的结果,当它们一起考虑时.
- 肺血管阻力≥3Wu是更糟糕的等待列表结果的重要预测因子,在这个人群中可以作为一个有价值的预后标志物.
更多相关视频
07:28Donor Posterior Atrial Flap Rotation for Left Atrial Cuff Reconstruction in Lung Transplantation
Published on: October 11, 2024
284
09:54Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
1.7K
相关概念视频
01:30Pulmonary Hypertension: Classification and Pathogenesis
138
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
138
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
118
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
118
01:29Pulmonary Tuberculosis I
212
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
212
01:27Pneumothorax-II
111
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
111
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
139
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
139